Elastin-like polypeptide, and preparation method therefor and use thereof

By developing elastin-like polypeptides as drug carriers, using their temperature responsive characteristics to form a drug reservoir, the problem of insufficient release time and space control and targeting in drug delivery is solved, and efficient and safe drug delivery effect is achieved. Suitable for the treatment of a variety of diseases.

WO2024240103A1PCT designated stage expired Publication Date: 2024-11-28HUNAN ZONSEN PEPLIB BIOTECH CO LTD

Patent Information

Application Number
PCT/CN2024/094122
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-20
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The prior art has problems in drug release time and space control, insufficient targeting and poor drug carrier performance in drug delivery, especially in the treatment of multiple diseases, especially in the treatment of cancer and other chronic diseases, which requires more Efficient and safe drug delivery regimen.

Method used

Develop an elastin-like polypeptide (ELP) with an amino acid sequence of (VPGXG) n, where X includes I, A and F, which is expressed through genetic engineering and combined with drugs, and uses temperature-responsive characteristics to form a drug reservoir to realize drugs slow release and targeted delivery.

Benefits of technology

It realizes slow release and local delivery of drugs, improves the therapeutic effect of drugs, reduces the toxic effect on normal tissues, prolongs the half-life of drugs, and can accurately control the release position and time of drugs, and is suitable for the treatment of various diseases. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024094122-FTAPPB-I100001
    Figure PCTCN2024094122-FTAPPB-I100001
  • Figure PCTCN2024094122-FTAPPB-I100002
    Figure PCTCN2024094122-FTAPPB-I100002
  • Figure 00000014_0000
    Figure 00000014_0000
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine, in particular to an elastin-like polypeptide, and a preparation method therefor and the use thereof. The amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X comprises I, A and F, and n is an integer selected from 20 to 120. The elastin-like polypeptide has a reversible phase-change temperature, a simple purification method, and good and controllable release capability. The elastin-like polypeptide can be used as a drug reservoir and can be conjugated to various drugs. The elastin-like polypeptide can improve the treatment effect of carried drugs and make targeted therapy more accurate.
Need to check novelty before this filing date? Find Prior Art

Description

Elastin-like polypeptide and its preparation method and application Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to an elastin-like polypeptide and a preparation method and application thereof. Background Art

[0002] Elastin is an important extracellular matrix protein that mainly exists in the connective tissue of arteries, skin, lungs and ligaments. In the body, it can combine with microfibrils to form elastic fibers, and together with collagen fibers, it gives tissues elasticity and tensile strength.

[0003] Elastin-like polypeptides (ELPs) are repetitive artificial polypeptides derived from the repetitive amino acid sequence in the hydrophobic domain of tropoelastin. Their structure primarily consists of a series of repeating pentapeptide units (Val-Pro-Gly-Xaa-Gly, VPGXG), where Xaa is any amino acid except proline. Because different amino acids have distinct structures and functions, ELPs can exhibit different biological functions depending on the Xaa sequence.

[0004] Elastin-like polypeptides exhibit reversible phase transition behavior with temperature. Below their transition temperature (Tt), elastin-like polypeptides are soluble, while above their Tt, they become insoluble and aggregated. Different amino acids represented by X result in different properties of elastin-like polypeptides. Specifically, if X is a hydrophobic amino acid, the phase transition temperature increases. Based on the different properties, proportions, and repetitions of X, elastin-like polypeptides or elastin-like polypeptide fusion proteins with different phase transition temperatures can be designed. When elastin-like polypeptides exhibit reversible phase transitions to a condensed state, the recombinant protein can be separated by centrifugation, resulting in simple protein separation. This property allows for rapid purification of the prepared elastin-like polypeptides.

[0005] Elastin-like peptides exhibit unique temperature responsiveness, exhibiting a thermodynamically reversible phase transition above the phase transition temperature. The β-turn structure of the repeating unit at the Pro-Gly residue transforms from an extended and disordered state to a more compact, right-handed β-helix. Further increases in temperature cause the β-helices to aggregate. Within the phase transition temperature range, a certain number of amino acids are observed, forming β-sheets within the chain, further promoting cross-linking and aggregation between elastin-like peptide chains. This transforms the peptide into an ordered polymer in an aqueous environment, primarily driven by hydrophobic residues, which facilitates the packaging of hydrophobic drugs.

[0006] Therefore, the phase transition temperature can be precisely controlled by adjusting the sequence and length of elastin-like polypeptides to tailor drug release and targeting, both temporally and spatially, based on the characteristics and therapeutic needs of different drugs. Furthermore, elastin-like polypeptides can be genetically engineered to link the sequences of a pharmaceutical protein and an elastin-like polypeptide to express a fusion protein. Corresponding active groups can be designed into the elastin-like polypeptide chain, and the drug can be covalently conjugated to the elastin-like polypeptide chain through a chemical reaction with the drug, forming an ELPs-DOX conjugate. Furthermore, pharmaceutical proteins or small molecule drugs can be directly encapsulated into elastin-like polypeptides, allowing them to self-assemble into microparticles, nanobeams, or micelles. Elastin-like polypeptides exhibit excellent pharmacokinetic properties when used as drug carriers. To achieve slow release of pharmaceutical proteins or small molecule drugs within elastin-like polypeptides, their phase transition temperature is first adjusted to below physiological temperature. This allows a phase transition to occur at the injection site after injection, forming a drug reservoir. This reservoir ensures slow drug release, achieving long-term efficacy or localized drug delivery. Furthermore, because elastin-like peptides are composed of natural amino acids, they exhibit excellent biocompatibility, are easily biodegradable, have low immunogenicity, and are non-toxic. Using elastin-like peptides as drug carriers can effectively extend drug half-life, increase the solubility of poorly soluble drugs, and reduce their toxic effects on normal tissues and organs. These advantages have broad applications in biopharmaceutical fields, including protein expression and purification, drug delivery, in vitro diagnostics, and tissue engineering.

[0007] Many ELPs have been discovered that can be used as drug carriers to treat various diseases, including siEVI1-ELP for the treatment of various cancers (breast cancer, ovarian cancer, pancreatic cancer and lung cancer), VIP-ELP for the treatment of pulmonary hypertension, cardiomyopathy, cystic fibrosis, GLP1-ELP for the treatment of type 2 diabetes, and (VPGVG) as a reservoir for the treatment of neuroinflammation. 120 and (VPGVG) 240 Therefore, ELP development is one of the most promising areas in drug delivery.

[0008] Elastin-like peptides are suitable candidates for new-age drug delivery and regenerative medicine, especially with increasing attention to the side effects, long-lasting effects, and half-life of small molecule drugs, as well as the increasing focus on high-efficiency and safe performance. Therefore, there is a need to develop more elastin-like peptides with good performance to accelerate the application, transformation, and development of elastin-like peptides in drug delivery.

[0009] Summary of the Invention

[0010] To address the deficiencies of the prior art, the present invention aims to provide an elastin-like polypeptide and a method for preparing the same, as well as the use of the elastin-like polypeptide as a drug carrier.

[0011] To achieve the above objectives, the present invention adopts the following technical solutions.

[0012] In one aspect, the present invention provides an elastin-like polypeptide having an amino acid sequence of (VPGXG)n, wherein X comprises I, A and F, and n is selected from an integer of 20 to 120.

[0013] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, and F, and n is an integer selected from 20 to 120.

[0014] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, and F, and n is an integer selected from 50 to 100.

[0015] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, and F, and n can be selected from 50 or 100.

[0016] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, and F, and n is 100.

[0017] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, and F, and the number of amino acids is I:A:F=2:2:1.

[0018] Preferably, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A and F, the number of amino acids is I:A:F=2:2:1, and n is 100.

[0019] Further preferably, the elastin-like polypeptide is 20 A 20 I 20 F 20 A 20 , and has the amino acid sequence shown in SEQ ID NO:3.

[0020] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X comprises I, A, F, and L, and n is an integer selected from 20 to 120.

[0021] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F, and L, and n is an integer selected from 60 to 120.

[0022] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F, and L, and n can be selected from an integer of 60 or 120.

[0023] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F, and L, and n is 120.

[0024] In some embodiments, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F, and L, and the number of amino acids is I:A:F:L=2:2:1:1.

[0025] Preferably, the amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F and L, the number of amino acids is I:A:F:L=2:2:1:1, and n is 120.

[0026] Further preferably, the elastin-like polypeptide is 20 A 20 I 20 F 20 A 20 L 20 , and has the amino acid sequence shown in SEQ ID NO:4.

[0027] In some embodiments, in the amino acid sequence of the elastin-like polypeptide of the present invention, to ensure seamless sequence connection, I, A, F, and L in the sequence are each independently replaced by V.

[0028] In some embodiments, to ensure seamless sequence connection, the first I, A, or F of each monomeric ELP module in the amino acid sequence of the elastin-like polypeptide of the present invention is replaced with V.

[0029] In some embodiments, to ensure seamless sequence connection, I, A, F or L in the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO: 4 are each independently replaced by V.

[0030] In some embodiments, to ensure seamless sequence connection, the first I, A, and F of each monomer ELP module in the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO: 4 are replaced with V.

[0031] In some embodiments, the elastin-like polypeptide further comprises a leader peptide, which can enhance the expression level of the elastin-like polypeptide.

[0032] In some embodiments, the amino acid sequence of the elastin-like polypeptide further comprises a leader peptide, and the leader peptide is selected from MGSSGLVPRGSKGPG and MSKGPG.

[0033] Preferably, the leader peptide is MSKGPG.

[0034] In some embodiments, the elastin-like polypeptide further comprises a trailer peptide, which is capable of controlling the size, shape and stability of the nanostructure of the elastin-like polypeptide.

[0035] In some embodiments, the tail peptide is (Φ(G)y)z, wherein Φ represents tyrosine (Tyr, Y), phenylalanine (Phe, F) or tryptophan (Trp, W), y represents the number of glycine spacers (y = 0, 1 or 2), and z is selected from an integer from 0 to 8.

[0036] Preferably, the tail peptide is (Φ(G)y)z, wherein Φ represents tyrosine (Y), that is, the structure of the tail peptide is [Y(G)y]z.

[0037] In some embodiments, the tail peptide is selected from YGYGYGYGYGYGY, YGYGYGYGYGYGYG, YGGYGGYGGYGGYGGYGGYGG.

[0038] In some embodiments, the tail peptide is YGYGYGYGYGYGY.

[0039] Preferably, the amino acid sequence of the elastin-like polypeptide is as shown in SEQ ID NO: 1 or SEQ ID NO: 2:

[0040] In another aspect, the present invention provides a polynucleotide comprising a sequence encoding the above-mentioned elastin-like polypeptide.

[0041] In another aspect, the present invention provides a recombinant expression vector comprising the sequence of the polynucleotide described above.

[0042] In another aspect, the present invention provides a genetically engineered bacterium, which is Escherichia coli containing the above-mentioned recombinant expression vector.

[0043] In another aspect, the present invention provides a method for preparing the above-mentioned elastin-like polypeptide, the method comprising:

[0044] (1) ELP monomer gene amplification: NdeI-PflM restriction site was added to the N-terminus and BglI-HindIII restriction site was added to the C-terminus of the ELP monomer gene module, and the gene was amplified to the target size by PCR;

[0045] (2) Construction of ELP monomer gene module expression plasmid: The ELP monomer gene was ligated into the pET plasmid and verified to be correct by digestion with NdeI and HindIII and sequencing;

[0046] (3) The plasmid expressing the ELP monomer gene module was digested with PflM to form a linearized plasmid I, and then double-digested with PflM and BglI to form a linearized plasmid II. The ELP monomer gene was purified and recovered using a DNA purification kit. The linearized plasmid I obtained by single-digestion and the linearized plasmid II obtained by double-digestion were ligated overnight under the action of T4 ligase to obtain a recombinant plasmid.

[0047] (4) transfecting the obtained recombinant plasmid into Escherichia coli to induce expression;

[0048] (5) crushing the E. coli obtained in step (4) to obtain a soluble protein solution containing the target protein;

[0049] (6) Elastin-like polypeptides were purified by reversible phase change cycle method.

[0050] Furthermore, the plasmid in step (2) is pET15b.

[0051] Furthermore, the specific method of the crushing treatment in step (6) is at least one of ultrasonic crushing, homogenization crushing, ball milling crushing, repeated freeze-thaw crushing and lysozyme enzymatic crushing.

[0052] Furthermore, the reversible phase change cycle method in step (7) includes the following steps:

[0053] Add NaCl solid to the supernatant to a final concentration of 2 mol / L, incubate in a 42°C water bath for 15 min, centrifuge at 12,000 rpm / min for 15 min, and remove the supernatant; add 35 mL of PBS solution to the precipitate to dissolve the precipitate, transfer it to a 50 mL conical-bottom centrifuge tube, rotate in a refrigerator for 1 h, centrifuge at 4°C and 12,000 rpm / min for 15 min, and collect the supernatant; repeat the above steps and add NaCl solid to the supernatant to a final concentration of 2 mol / L, collect the precipitate, add 5 mL of PBS solution at 4°C to dissolve the precipitate, centrifuge at 4°C and 12,000 r / min for 15 min, and collect the supernatant.

[0054] The elastin-like polypeptide of the present invention has a reversible phase transition temperature. Based on this property, when the temperature is higher than the phase transition temperature, the elastin-like polypeptide aggregates to form particles; when the temperature is lower than the phase transition temperature, the elastin-like polypeptide disperses in the solution, and the solution becomes clear. Based on this property, the elastin-like polypeptide can be used to separate and purify.

[0055] In yet another aspect, the present invention further provides a use of the above-mentioned elastin-like polypeptide in preparing a drug delivery system.

[0056] In some embodiments, the elastin-like polypeptides of the present invention contain active groups at their ends, which can bind to drugs or markers to couple and release the drugs.

[0057] In some embodiments, the elastin-like polypeptide synthesized in the present invention has an optimal phase transition temperature and exists in a solution state at room temperature. When injected into the human body at body temperature, the elastin-like polypeptide solidifies at the lesion site and does not spread as a whole.

[0058] In some embodiments, the aforementioned elastin-like polypeptide is degradable and its injection site is controllable.

[0059] In some embodiments, the elastin-like polypeptides have good release capacity and a good release effect within a certain period of time.

[0060] In some embodiments, the elastin-like polypeptides of the present invention have good drug release capabilities. Therefore, the types of packaged drugs are diverse, including therapeutic proteins (interleukins, tumor necrosis factors, corticosteroids and enzymes, monoclonal antibodies, therapeutic vaccines, insulin, interferon, etc.), and radionuclide drugs. In addition, the elastin-like polypeptides are developed as a degradable, injectable, customizable, close-range, continuous elastin-like polypeptide reservoir. Its treatment method is to utilize the thermosensitive aggregation and cross-linking properties of ELP to form a reservoir, so that the carried drug is retained at the injection site by direct or interventional injection. In this way, the drug release is precisely controlled for distribution, and the speed and release time of the drug are controlled. The target area and safety margin can be set, so that harmful cells can be killed at close range without affecting the surrounding healthy tissues, so that the lesions are reduced or eliminated, or organ function is improved, or auxiliary organs are retained, so as to achieve the purpose of improving the patient's quality of life and prolonging survival.

[0061] The elastin-like polypeptide of the present invention exists in the form of a reservoir and can be coupled with a variety of drugs, and has the following advantages:

[0062] (1) The release capacity of this type of elastin polypeptide is controllable, which can improve the therapeutic effect of the carried drug;

[0063] (2) It can make targeted therapy more accurate and improve the enrichment of drugs at the tumor site. The phase transition temperature of the two elastin-like polypeptides of the present invention is lower than the human body temperature and can aggregate and solidify when injected into the human body;

[0064] (3) It can control the dosage of drugs, thereby reducing the toxic and side effects of drugs.

[0065] the term

[0066] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0067] In the context of the present disclosure, the term "amino acid" is defined as having at least one primary, secondary, tertiary or quaternary amino group and at least one acid group, wherein the acid group can be a carboxylic acid, a sulfonic acid or a phosphoric acid or a mixture thereof. The amino group can be "α", "β", "γ" to "ω" relative to the acid group. Suitable amino acids include, but are not limited to, the D- and L-isomers of the 20 common naturally occurring amino acids found in peptides (e.g., alanine, arginine, asparagine, cysteine, glutamine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine) and naturally occurring and non-naturally occurring amino acids prepared by organic synthesis or other metabolic pathways.

[0068] The amino acids mentioned in the present invention are abbreviated as follows according to the IUPAC-IUB nomenclature:

[0069] Alanine (Ala, A); Arginine (Arg, R); Asparagine (Asn, N); Aspartic acid (Asp, D); Cysteine ​​(Cys, C); Glutamic acid (Glu, E); Glutamine (Gln, Q); Glycine (Gly, G); Histidine (His, H); Isoleucine (Ile, I); Leucine (Leu, L); Lysine (Lys, K); Methionine (Met, M); Phenylalanine (Phe, F); Proline (Pro, P); Serine (Ser, S); Threonine (Thr, T); Tryptophan (Trp, W); Tyrosine (Tyr, Y); Valine (Val, V).

[0070] The terms "polypeptide," "peptide," and "amino acid sequence" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer may be linear or branched, it may contain modified amino acids or amino acid analogs, and may be interrupted by non-amino acid chemical moieties. The term also includes amino acid polymers that have been modified naturally or artificially, such as by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation to a label or biologically active component. The term "peptide" includes two or more naturally occurring or synthetic amino acids linked by covalent bonds, such as amide bonds.

[0071] The term "including" is used to mean "including but not limited to".

[0072] The term "buffer" refers to a buffered solution that resists changes in pH through the action of its acid-base conjugate components.

[0073] Compared with the prior art, the present invention has at least the following beneficial effects:

[0074] (1) The method for purifying the elastin-like polypeptide of the present invention is simple, reduces the preparation cost, and can achieve large-scale separation and purification of elastin-like proteins.

[0075] (2) The present invention provides a novel elastin-like polypeptide, provides a new structure for elastin-like polypeptides, enriches the types of ELPs, and provides a new type of drug carrier.

[0076] (3) The elastin-like polypeptide of the present invention has good release capacity both in vivo and in vitro, and the release capacity is controllable, which can improve the therapeutic effect of the carried drug. The phase transition temperature fluctuates around 15-20°C, which is lower than the human body temperature, and is suitable as a drug carrier for drug delivery.

[0077] (5) The elastin-like polypeptide of the present invention can act as a drug reservoir, can be coupled with a variety of drugs, is degradable, injectable, integrally solidified, does not migrate, and has a controllable release capacity within a certain range. It can be used as a package for drugs that require targeted treatment, such as radionuclide drugs, and can accurately control the radiation dose and injection location, with a safety margin, so that it can kill diseased tissues at close range without damaging surrounding normal tissues and organs. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 is a diagram showing the ITC purification results of ELPs shown in SEQ ID NO: 1 and SEQ ID NO: 2, wherein Figure 1A shows the purification results of ELPs shown in SEQ ID NO: 1, Figure 1B shows the purification results of ELPs shown in SEQ ID NO: 2, and Figure 1C shows the purity verification of ELPs shown in SEQ ID NO: 1(1) and SEQ ID NO: 2(2), with a concentration of 15 μM and a sample volume of 10 μL;

[0079] Figure 2 shows the OD values ​​of ELPs shown in SEQ ID NO: 1 and SEQ ID NO: 2 in PBS buffer. 350 2A shows the change in turbidity of the ELPs shown in SEQ ID NO: 1 as the temperature increases, and FIG. 2B shows the change in turbidity of the ELPs shown in SEQ ID NO: 2 as the temperature increases;

[0080] Figure 3 shows the repeated phase transition diagram and OD of ELPs shown in SEQ ID NO: 1 and SEQ ID NO: 2 350 Detection phase transition temperature change diagram, wherein Figure 3A is the ELPs repeated phase transition diagram shown in SEQ ID NO: 1 and SEQ ID NO: 2, and Figure 3B is the ELPsOD shown in SEQ ID NO: 1 350 Detection of phase transition temperature change diagram, Figure 3C is the ELPs OD shown in SEQ ID NO: 2 350 Detect phase change temperature change diagram;

[0081] Figure 4 is a graph showing the relationship between the amount of fluorescence released in vitro and time of FITC-labeled ELPs shown in SEQ ID NO: 1 and SEQ ID NO: 2 simulating blood circulation, wherein Figure 4A is a graph showing the relationship between the amount of fluorescence released in vitro and time of SEQ ID NO: 1 ELPs simulating blood circulation, and Figure 4B is a graph showing the relationship between the amount of fluorescence released in vitro and time of SEQ ID NO: 2 ELPs simulating blood circulation;

[0082] Figure 5 is a graph showing the relationship between the release ability of ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 at different concentrations in mice and time, wherein Figure 5A is a graph showing the relationship between the release ability of ELPs represented by SEQ ID NO: 1 in mice and time, and Figure 5B is a graph showing the relationship between the release ability of ELPs represented by SEQ ID NO: 2 in mice and time. Specific embodiments

[0083] The present invention will be further described in detail below with reference to specific embodiments. The embodiments of the present invention are only for illustrating the technical ideas and features of the present invention, and are not intended to limit the scope of protection of the present invention.

[0084] Example 1 Purification of ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2

[0085] 1. Construction of SEQ ID NO: 1 and SEQ ID NO: 2 monomer modules

[0086] (1) Construction of leader peptide and tail peptide vector pET-V: The leader peptide and tail peptide DNA sequences were connected, NcoⅠ-MSKGPGWPYGYGYGYGYGYGY-XhoⅠ, the sequence is shown in SEQ ID No. 5, and the sequence was synthesized and connected into the pET15b plasmid, and the enzyme digestion of NcoⅠ and XhoⅠ and sequencing were verified.

[0087] (2) Monomeric ELP module plasmid construction: 20 pentapeptide linker modules such as (VPGVG)1(VPGIG) 19 、(VPGVG)1(VPGAG) 19 、(VPGVG)1(VPGFG) 19 、(VPGLG) 20 As shown, NdeI-PflM I and BglI-HindIII restriction sites were added to the N-terminus and C-terminus respectively during construction. The DNA sequences of the connecting modules of the above 20 pentapeptides are shown in SEQ ID No.6 to SEQ ID No.9, wherein SEQ ID No.6 is (VPGVG)1(VPGIG) 19 The DNA sequence of SEQ ID No.7 is (VPGVG)1(VPGAG) 19 The DNA sequence of SEQ ID No. 8 is (VPGVG)1(VPGFG) 19 The DNA sequence of SEQ ID No.9 is (VPGLG) 20 The DNA sequence was annealed and connected to the pUC18 plasmid, which was verified by NdeⅠ and HindⅢ enzyme digestion and sequencing, and the pUC18-ELP (V1I 19 )、pUC18-ELP(V1A 19 )、pUC18-ELP(V1F 19 )、pUC18-ELP(L 20 ) plasmids, etc.

[0088] 2. Construction of SEQ ID NO: 1 and SEQ ID NO: 2

[0089] (1)pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 ) and pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 )Plasmid construction: pUC18-ELP(V1A 19 ) plasmid was linearized by PflM I single enzyme digestion and recovered after dephosphorylation; pUC18-ELP(V1F 19 The plasmid was digested with PflM and BglI to recover the monomer fragments, and the two were ligated with T4 DNA ligase. After transformation into Top10 competent cells, the plasmid was extracted and verified by NdeⅠ / / HindⅢ digestion or sequencing. The pUC18-ELP(V1F 19 V1A 19 Repeat the above steps until pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 ) and pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 ). pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 ) in which the DNA sequence between NdeI and HindIII is shown in SEQ ID No. 10, and the DNA sequence between NdeI and HindIII in pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 ) The DNA sequence between NdeI and HindIII is shown as SEQ ID No.11.

[0090] (2)pET15b-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A19 ) and pET15b-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 ) Construction of expression plasmid: pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 ) and pUC18-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 ) was double-digested with PflM and BglI to recover the target fragment; the pET-V plasmid was linearized with SfiⅠ and recovered after dephosphorylation. The linearized vector and the target fragment were ligated with T4 DNA ligase and transformed into Arctic Express competent cells. After plasmid extraction, NcoⅠ and XhoⅠ enzyme digestion were used for verification. pET15b-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 ) and pET15b-ELP(V1I 19 V1A 19 V1I 19 V1F 19 V1A 19 L 20 ) plasmid.

[0091] 3. Protein Expression and Purification

[0092] (1) Activation: Inoculate the successfully constructed expression vector and activate it. Then, expand the culture into 300 mL of TB liquid medium. Add 1 / 1000 ampicillin and 1 / 10 phosphate buffer solution and culture at 37°C for 5-6 hours. Add IPTG to a final concentration of 1 mM (1 / 1000). After induction at 37°C for 3 hours, centrifuge the culture at 4000 rpm for 5 minutes at 4°C, collect the cells, and discard the supernatant.

[0093] (2) Ultrasonic disruption: Add 1×PBS solution to each bottle of bacteria to 50 mL and resuspend, then disrupt with ultrasound (power 60%) for 10 min, centrifuge on ice, and collect the supernatant.

[0094] (3) ITC (Inverse transition cycling) purification: add NaCl solid to the supernatant to a final concentration of 2 mol / L, incubate at 42°C in a water bath for 15 min, centrifuge at 12,000 rpm / min for 15 min, and remove the supernatant; add 35 mL of PBS solution to the precipitate to dissolve the precipitate, transfer it to a 50 mL conical bottom centrifuge tube, rotate it in the refrigerator for 1 h, centrifuge it at 4°C and 12,000 rpm / min for 15 min, and collect the supernatant; repeat the above steps and add NaCl solid to the supernatant to a final concentration of 2 mol / L, collect the precipitate, add 5 mL of PBS solution at 4°C to dissolve the precipitate, centrifuge it at 4°C and 12,000 r / min for 15 min, and collect the supernatant. SDS-PAGE was used to detect the protein size and purity. Figures 1A and 1B show that the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 were successfully purified. Figure 1C shows that at a concentration of 15 μM and a sample volume of 10 μL, the protein bands were clean, without any other bands, and the purity was >95%.

[0095] Example 2 ELPs Thermal Characterization Study

[0096] The OD values ​​of ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 at concentrations of 25 μM, 125 μM, 250 μM, 500 μM, 750 μM and 1000 μM were measured using a carry 3500 UV-Vis spectrometer. 350 , set the temperature range to 5~30℃, and measure OD every 0.5℃ / min 350 Figure 2 shows the turbidity curves of the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 at various concentrations. As can be seen from the figure, the phase transition temperature of the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 decreases with increasing concentration, and it is found that the phase transition temperature of the ELPs fluctuates around 15-20°C, which is lower than the human body temperature, indicating that the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 are suitable for use as human drug carriers.

[0097] Example 3 ELPs Stability Study - Repeated Phase Transition Study

[0098] Based on the phase transition temperatures measured at each concentration above, a constant temperature water bath was set at 40°C, and 1 mL of a 25 μM sample was taken. Six repeated phase transitions were performed between 40°C and 4°C, and the change in phase transition temperature after repeated phase transitions was measured. As shown in Figure 3A, the ELPs were able to return to a clear state at low temperatures after repeated phase transitions. Figure 3B shows that the phase transition temperatures of the ELPs represented by SEQ ID NO:1 and SEQ ID NO:2 remained essentially unchanged after six repeated phase transitions, with the phase transition temperature of the ELPs represented by SEQ ID NO:1 remaining at approximately 18.6°C and the phase transition temperature of the ELPs represented by SEQ ID NO:2 remaining at approximately 19.8°C.

[0099] Example 4 In vitro release study of ELPs

[0100] The ELPs represented by SEQ ID NO:1 and SEQ ID NO:2 were buffered by ITC with NaHCO3 buffer (pH = 8.5) to a 5 mg / mL protein solution (rotated at 4°C until completely dissolved). FITC was dissolved in 100% DMSO to a concentration of 20 mg / mL. The FITC solution and ELP solution were mixed at a molar ratio of 10:1 at 4°C and incubated with rotation overnight. Two rounds of ITC were performed using phase change properties to separate the ELP-fluorophore conjugate from unreacted fluorophore. After one round of ITC, the tube walls were briefly flushed with PBS (37°C), and the original volume of PBS was added and incubated at 4°C with rotation until completely dissolved. After two rounds of ITC, 2 mL of PBS was added and the solution was dissolved with rotation at 4°C. Meanwhile, an unlabeled sample was prepared.

[0101] The FITC-labeled ELP was spiked into the unlabeled sample in half to a final concentration of 1 mM. The total fluorescence of the 1 mM sample was calculated. Three concentrations of 250 μM, 500 μM, and 750 μM were set, with three groups of 500 μL each. The treated samples and the control group were placed in a 37°C incubator. After natural sedimentation, they were centrifuged at 12,000 rpm for 2 minutes and incubated with rotation to simulate human blood flow. 500 μL of the sample was collected at 0 h, 24 h, 4 days, 12 days, 20 days, 30 days, 40 days, 50 days, 60 days, 72 days, 82 days, and 100 days, and the sample was replenished with 500 μL of PBS solution. The samples and standard samples were measured using a multifunctional microplate reader, and the fluorescence values ​​of the samples were measured according to the standard curve. The data were processed to confirm the release capacity of the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2. The results are shown in Figure 4. When the ELP concentration is high, the release ability is weak. On the contrary, when the concentration is low, the release ability is strong. The results show that the cumulative release of ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 at concentrations of 250 μM, 500 μM and 750 μM within 100 days is less than 50%, indicating that the ELPs represented by SEQ ID NO: 1 and SEQ ID NO: 2 have a good half-life and can maximize the release of the drug.

[0102] Example 5 Endotoxin Level Assessment

[0103] To ensure that endotoxins do not affect the in vivo stability experiment, causing endotoxins to exceed the standard and lead to hemorrhagic fever and death in mice, this experiment uses Endotoxin Removal Beads to remove endotoxins and uses Limulus amebocyte lysate to detect endotoxin limits.

[0104] Thoroughly mix the Endotoxin Removal Beads. Using a pyrogen-free pipette tip, pipette 1 mL of the slurry into the chromatograph. Open the lower outlet and remove the protective buffer. Rinse with 3 mL of regeneration buffer, controlling the flow rate to 0.25 m / min, or less than 10 drops per minute, and the temperature to 2-8°C. Repeat at least twice to ensure the column is free of endotoxin.

[0105] Use 3 mL of equilibration solution to equilibrate the inner wall of the column tube and the filler, drain until dry, with a flow rate of about 0.5 mL / min and the temperature controlled at 2-8°C. Repeat at least twice.

[0106] Add the sample to the balanced Endotoxin Removal Beads and adjust the flow rate to 0.25 m / min, or less than 10 drops per minute. When the effluent flows out for about 1 m, start collecting the effluent. After it dries up, add 1 mL of equilibration solution and continue collecting.

[0107] The endotoxin content in the samples was detected by Limulus amebocyte lysate (endotoxin content was lower than the international standard (radioinjection K = EU2.5 / gh)f). The endotoxin detection level is shown in Table 1:

[0108] Table 1 Endotoxin detection levels of SEQ ID No: 1 and SEQ ID No: 2

[0109] The results show that the endotoxin content in the ELPs sample of the present invention is low, which can ensure the safety of clinical medication.

[0110] Example 6 In vivo experimental release study

[0111] To study the release ability and stability of the ELP in vivo, the release ability and stability of the ELP were detected by injecting Cy5.5-labeled ELP into mice and observing the decay of fluorescence values.

[0112] The corresponding Cy5.5 (10 mg / mL) was added to ELP (5 mg / mL, NaHCO3 solution, pH 8.4) at a molar ratio of Cy5.5:ELP = 2:1. The mixture was rotated and labeled overnight at 4°C in the dark. The ELP-fluorophore conjugate was separated from the unreacted fluorophore by ITC and PD-10 chromatography column. The Cy5.5-ELP concentration was determined using a carry 3500 UV-Vis spectrometer, and the fluorescence value of the labeled sample was verified.

[0113] Cy5.5-ELP was mixed with unlabeled ELP (250 μM, 500 μM, and 750 μM) and injected. Nude mice were anesthetized with an inhalation anesthetic (1%, w / v, isoflurane in 2 L of oxygen) by weighing and then injected with approximately 25 μL of the ELPs-Cy5.5 solution. In vivo fluorescence images and near-infrared fluorescence magnitude were captured using a near-infrared imaging instrument at various time intervals (0 days, 7 days, 14 days, 19 days, 28 days, 35 days, 42 days, 49 days, 56 days, 63 days, 70 days, 77 days, 84 days, and 92 days) after anesthesia. The results are shown in Figure 5.

[0114] The data in Figure 5 show that the cumulative fluorescence released by the ELPs represented by SEQ ID NO:1 and SEQ ID NO:2 is within a controllable range. SEQ ID NO:1 can still maintain approximately 80% of its fluorescence after 70 days in vivo. Compared with the in vitro release experiment, the release capacity of SEQ ID NO:2 at the same concentration level in vivo is stronger than that in vitro. This may be due to the presence of multiple enzymes and other substances in the body that can degrade ELPs. This shows that ELPs are qualified to serve as local drug reservoirs and can control the release effect of drugs.

[0115] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An elastin-like polypeptide, characterized in that: The amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X includes I, A and F, and n is selected from an integer of 20 to 120.

2. The elastin-like polypeptide according to claim 1, characterized in that The amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A and F, the number of amino acids in the elastin-like polypeptide is I:A:F=2:2:1, and n is 100; preferably, the elastin-like polypeptide is I 20 A 20 I 20 F 20 A 20 , and has an amino acid sequence as shown in SEQ ID NO:

3.

3. The elastin-like polypeptide according to claim 1, characterized in that The amino acid sequence of the elastin-like polypeptide is (VPGXG)n, wherein X is I, A, F and L, the number of amino acids in the elastin-like polypeptide is I:A:F:L=2:2:1:1, and n is 120; preferably, the elastin-like polypeptide is I 20 A 20 I 20 F 20 A 20 L 20 , and has an amino acid sequence as shown in SEQ ID NO:

4.

4. The elastin-like polypeptide according to any one of claims 1 to 3, characterized in that The first I, A, and F of each monomer ELP module in the elastin-like polypeptide is replaced by V.

5. The elastin-like polypeptide according to any one of claims 1 to 4, characterized in that The elastin-like polypeptide further comprises a leader peptide and a tail peptide, wherein the leader peptide is selected from MGSSGLVPRGSKGPG and MSKGPG, and the tail peptide is selected from YGYGYGYGYGYGYG, YGYGYGYGYGYGYG, and YGGYGGYGGYGGYGGYGGYGGG.

6. An elastin-like polypeptide, characterized in that: The amino acid sequence of the elastin-like polypeptide is shown in SEQ ID NO: 1 or SEQ ID NO:

2.

7. A polynucleotide, characterized in that The polynucleotide can encode the elastin-like polypeptide according to any one of claims 1 to 6.

8. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the polynucleotide according to claim 7.

9. A genetically engineered bacterium, characterized in that: The genetically engineered bacteria is Escherichia coli containing the recombinant expression vector according to claim 8.

10. Use of the elastin-like polypeptide according to any one of claims 1 to 6 in the preparation of a drug delivery system.

Citation Information

Patent Citations

  • SOD-ELP fusion protein and preparation method thereof

    CN111019962A

  • Purification method and application of ELP collagen

    CN112661856A

  • Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution

    US20110207673A1

  • Nanoparticulate drug delivery systems

    US20210316007A1

  • Cargo carrying nanoparticles

    US9616138B1

Cited By

  • Bioengineering-based elastin-like protein purification method

    CN119613535A